On Tuesday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) was -4.63% drop from the session before settling in for the closing price of $2.59. A 52-week range for BDTX has been $2.23 – $7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 30.85%. With a float of $42.89 million, this company’s outstanding shares have now reached $56.52 million.
In an organization with 54 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.97%, operating margin of -1662.46%, and the pretax margin is -1493.65%.
Black Diamond Therapeutics Inc (BDTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Black Diamond Therapeutics Inc stocks. The insider ownership of Black Diamond Therapeutics Inc is 24.20%, while institutional ownership is 75.31%. The most recent insider transaction that took place on Aug 28 ’24, was worth 1,400,556. In this transaction 10% Owner of this company sold 221,600 shares at a rate of $6.32, taking the stock ownership to the 3,726,341 shares. Before that another transaction happened on Jul 31 ’24, when Company’s Former Employer proposed sale 50,000 for $6.20, making the entire transaction worth $310,000.
Black Diamond Therapeutics Inc (BDTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 30.85% per share during the next fiscal year.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
You can see what Black Diamond Therapeutics Inc (BDTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.49 million. That was inferior than the volume of 0.79 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 59.77%. Additionally, its Average True Range was 0.20.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 3.60%, which indicates a significant decrease from 15.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.06% in the past 14 days, which was lower than the 77.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.21, while its 200-day Moving Average is $4.78. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $2.58. Second resistance stands at $2.68. The third major resistance level sits at $2.75. If the price goes on to break the first support level at $2.41, it is likely to go to the next support level at $2.34. The third support level lies at $2.24 if the price breaches the second support level.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
There are 56,585K outstanding shares of the company, which has a market capitalization of 139.77 million. As of now, sales total 0 K while income totals -82,440 K. Its latest quarter income was 0 K while its last quarter net income were -15,560 K.
